FDA recall D-1307-2022

Hikma Pharmaceuticals USA Inc. · Class II · drug

Product

Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6044-25, Vial NDC# 0641-6044-01

Reason for recall

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Distribution

Nationwide in the USA

Key facts

Status
Terminated
Initiation date
2022-07-11
Report date
2022-08-17
Termination date
2023-09-14
Voluntary/Mandated
Voluntary: Firm initiated
Location
Cherry Hill, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1307-2022